Semaglutide and its class of drugs: what you need to know

Step 1: where GLP-1 receptor agonists come from

The GLP-1 class grew out of an unlikely discovery, researchers in the 1980s noticed that a hormone called glucagon-like peptide-1 was released from the gut after a meal and had a powerful effect on insulin secretion and appetite. Early GLP-1 compounds broke down in the bloodstream within minutes, so pharmaceutical chemists spent decades engineering longer-acting analogues. Semaglutide, approved by the MHRA for use in the UK, is one of the most stable of these: its molecular structure has been modified so it binds to albumin in the blood, extending its half-life to roughly one week. That is why a single weekly injection (or, in the case of the oral Wegovy tablet, a once-daily dose) is enough to maintain consistent levels. The semaglutide page on our site covers the molecule itself in more detail if you want to go deeper on the pharmacology.

Other medicines in this class include liraglutide (Saxenda, Victoza) and, from a related but distinct mechanism, tirzepatide, which activates both GLP-1 and GIP receptors. If you are curious about where semaglutide fits among related treatments, our page on the semaglutide class explains the broader family of medicines it belongs to. Semaglutide activates GLP-1 only, making it a single-agonist within a broader receptor-agonist family.

Step 2: what semaglutide actually does once it is in your system

Once active, semaglutide works along several parallel pathways. In the brain's hypothalamus it reduces appetite signals, so most people find they feel full on less food and have fewer cravings between meals. In the gut, it slows gastric emptying, meaning food stays in the stomach longer and the sensation of fullness is extended. In the pancreas, it stimulates insulin release in a glucose-dependent way, insulin goes up only when blood sugar is elevated, which matters both for safety and for its diabetes application.

These effects compound over time. The STEP 1 trial, published in the New England Journal of Medicine, found that adults with obesity or overweight who used semaglutide 2.4mg weekly alongside lifestyle support lost an average of around 15% of their body weight over 68 weeks. That figure is a clinical-trial average for a specific population, individual responses vary, and a prescriber's role includes setting realistic expectations alongside treatment.

One practical detail that often surprises people: because gastric emptying slows, the timing of other medicines (particularly oral contraceptives) can be affected, something prescribers at our clinical team routinely factor into assessments.

Step 3: how the licensed UK products differ within the class

Understanding the class means understanding that the same molecule can have quite different clinical profiles depending on dose and formulation. At the doses used in Ozempic (up to 1mg, with a 2mg option for diabetes), semaglutide is licensed to improve blood sugar control in type 2 diabetes, not for weight loss. At the higher doses used in Wegovy (up to 2.4mg weekly by injection, or 25mg daily by tablet), the same molecule is licensed specifically for weight management. The MHRA also approved a 7.2mg Wegovy pen in April 2026, confirmed on GOV.UK, for adults with a BMI of 30 or above only.

The oral Wegovy tablet (approved by the MHRA in June 2026, making the UK the first country in Europe to license an oral GLP-1 for weight management) is co-formulated with an absorption enhancer called SNAC. It needs to be taken first thing in the morning on an empty stomach, with a small amount of plain water, and food or other medicines should wait at least 30 minutes. No refrigeration is required, which many patients find genuinely useful when travelling or during months where keeping a schedule is harder (payday weekends, bank holidays, the routine-disruptions that can catch people out with injectable treatments).

For anyone weighing up which formulation suits their life, the page on the highest-dose semaglutide options and our Wegovy cost overview cover those angles in full.

Step 4: where semaglutide sits in UK clinical pathways

Semaglutide for weight management is a prescription-only medicine, and the NHS route is specifically structured: NICE TA875 recommends Wegovy only within specialist weight management services, for a maximum of two years, for adults with a BMI of 35 or above (with at least one weight-related comorbidity) or in some cases 30–34.9, and with ethnic-background BMI thresholds set 2.5 kg/m² lower in relevant groups. NHS waiting lists for these services are often long.

Private treatment through a regulated pharmacy is the alternative for people who are clinically suitable but either don't meet the NHS criteria or prefer not to wait. The NHS notes on its semaglutide medicines page that this is a prescription medicine requiring clinical assessment, that holds for any route, NHS or private. If you want to understand your options across all licensed weight-loss treatments, our treatment overview is a useful starting point before speaking to a prescriber.

Semaglutide's semaglutide drug class also holds authorisations beyond weight management, a point worth understanding when discussing your options with a prescriber. Wegovy has a UK licence for reducing major cardiovascular event risk in eligible adults, and from July 2026 a conditional approval for a form of fatty liver disease (MASH). These indications are managed separately from weight management prescribing, and a prescriber will identify which, if any, applies to you.